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Clinical decisions for the treatment of localized
gastric cancer have become much more sophisticated
and complicated than ever. Two recent large-scale
trials published in NEJM for East Asian1 and Wes-
tern patients2 strongly support the routine use of
adjuvant chemotherapy. However, differences in de-
sign, extent of surgery, kind of chemotherapy timing
of administration, and survival results in the two
trials as well as potential differences in genetic
background of Asian and Western gastric caner pa-
tients raise critical questions and grow confusion and
uncertainty. Which is the optimum update treatment
for Western patients?
Is the Japanese model with standardized D2 sur-
gery followed by one year S-1 chemotherapy appli-
cable in the West and can it produce similar excellent
results or should treatment decisions be based on
Western patients data from the UK MAGIC trial2
and the USA INT-0116 trial?3 This editorial ap-
proaches this critical question towards a live-saving
decision. Emphasis is given to current advances in
network biology,4 cancer genome and functional
studies5–10 as well as a current comprehensive bench-
to-bedside genomic-based protocol for biomarkers-
based personalized treatment of gastric cancer.11
The landmark ACTS-GC Japanese study demon-
strated excellent survival results with primary stan-
dardized D2 surgery followed by S-1 chemotherapy
for advanced stages II and III.1 Most patients (89%)
had node-positive disease; these advanced tumor
stages are associated with poor prognosis in the
West.12 Despite this advanced disease, the overall 3-
year survival rate was 70% after D2 surgery alone
and 80% in the S-1 chemotherapy group. The hazard
ratio for death in the S-1 group, as compared with the
surgery-only group, was 0.68 (95% CI, 0.52–0.87;
p = 0.003). Because of this signiﬁcant survival dif-
ference the trial was stopped.
Local control is now increasingly recognized to
have a crucial role in the treatment strategy not only
of gastric cancer13–15 but also for many other solid
tumor including breast cancer despite the use of
adjuvant treatment.16,17 Appropriate surgery alone
or surgery plus radiotherapy for local control not
only reduce local recurrence but also improve
overall survival.17 This principle could be achieved
by a perfectly conducted standardized D2 surgery.
The 109 centers located throughout Japan were se-
lected from among hospitals performing at least 100
operations annually for gastric cancer. This high-
quality D2 surgery had resulted in a local relapse
rate of only 2.8% and a nodal relapse rate of 8.7%.
Adjuvant S-1chemotherapy signiﬁcantly reduced all
types of recurrence (peritoneal, local, nodal) but
questions arise form the ﬁnding that systemic
treatment did not improve hematogenous relapse
(p = 0.35).
The ACTS-GC study provides some important
messages but also raises several questions. First, can
the Japanese excellent results be reproduced in Wes-
tern patients? There is long-term discussion on whe-
ther there are diﬀerences between Japanese and
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Western gastric cancer and patients. Sakuramoto and
colleagues believe that these results can be achieved in
the West if a standardized, Japanese-style D2 surgery
is performed, because there is no genetic diﬀerence
between gastric cancers in Japan and Europe. Al-
though this may be correct, for deﬁnitive conclusions
much more in-depth research work is needed con-
sidering gastric cancer genome and interactions be-
tween environmental and genetic factors in Japan and
Europe or the USA. If all these genetic alterations
and environmental variables in carcinogenesis and
metastasis are similar, then indeed the Japanese re-
sults can be reproduced in the West. It should be
noted, however, that survival results for gastric can-
cer even with adequate D2 surgery in highly special-
ized Western institutions,18–20 are much lower than
those reported from Japan.1,13
Second, the Japanese study has demonstrated that
a substantial fraction of stage II/III patients had a
localized nature of disease. Indeed, the estimated
actuarial 5-year relapse-free survival was approxi-
mately 50% in the surgery-only group. How can
these patients be identiﬁed to spare chemotherapy
toxicity? Third, the addition of chemotherapy after
perfect local and nodal control could increase the
survival rate by 10%. How can this small survival
beneﬁt be further improved? These two questions are
discussed below as they can be approached consid-
ering current and future research directions towards
the development of both novel biomarkers and tar-
geted agents.
Preoperative and postoperative (perioperative)
chemotherapy with epirubicin, cisplatin, and ﬂuoro-
uracil was associated with a 5-year overall survival
beneﬁt of 13% (from 23% to 36%) for stage II or III
operable gastric cancer patients in the MAGIC trial
conducted mainly in the UK.2 In the USA INT-0116
trial,3 postoperative chemoradiotherapy improved
the 3-year overall survival from 41% to 50%. Both
trials have been criticized for inadequate surgery (D0
or D1). Thus, the approximately 30% survival dif-
ference between the Japanese trial1 and Western tri-
als2,3 could likely be explained by the fact that
chemotherapy or chemoradiotherapy simply com-
pensated mainly surgical failure for local and nodal
control.13,21,22 Another reason, beyond the potential
differences in body mass index that encourages an
‘‘easy’’ D2 surgery for Japanese patients, cancer
genome and environment, is also the inclusion of
patients with gastroesophageal junction tumors,
which are associated with poorer survival, in the
Western trials2,3 while such patients were excluded
from the Japanese study.
PERSONALIZED TREATMENT
Worldwide, despite improvements, estimated cure
rates for patients with stages IIIA and IIIB remain
poor. Given the short mean follow-up of 3 years in
the ACTS-GC study and the fact that a subset of
patients, approximately 20%, recur after the three
ﬁrst postoperative years,23 a cure rate of approxi-
mately 35% with surgery only and 45% by adding S-
1 chemotherapy to D2 surgery could be estimated.
These rates are currently the best achieved world-
wide; those reported from the West are lower despite
D2 surgery and adjuvant treatment.18–20,24,25 These
clinical data strongly indicate the urgent need to de-
velop new therapeutic strategies. .
How can long-term survival results be improved?
Despite intensive eﬀorts over recent decades, single-
gene-based traditional research has produced little
clinical success. No robust prognostic or predictive
marker has been validated for clinical use despite
multiple reports and hundreds of proposals.26 An
isolated success of traditional research towards per-
sonalized medicine for various cancer types27,28
including gastric cancer is the prevention and treat-
ment of hereditary diffuse gastric cancer (HDGC).29
Individuals who are carriers of germ-line mutations
in the CDH1 (E-cadherin) gene face a very high
lifetime risk of gastric cancer (60–80%).30 This very
small subpopulation can be identiﬁed from the very
large general population on the basis of family his-
tory criteria and genetic testing.30 Tailoring a risk-
reducing prophylactic gastrectomy for these very
high-risk individuals can save their lives.31 Women
with CDH1 mutations also have a high risk,
approximately 40%, of breast cancer.32 For these
carriers, as well as for women with germ-line BRCA1/
2 mutations,33 prophylactic bilateral mastectomy34,35
or close surveillance36 could be considered.37
But the management of sporadic cancer is much
more complicated because multiple genes and onco-
genic pathways are involved in gastric carcinogene-
sis.6 Obviously, single-gene-based traditional research
cannot reveal the global signaling pathways network.
Gastric cancer is a biologically heterogeneous disease
with various molecular tumor subsets that likely re-
spond distinctly differently and require new thera-
peutics for complete response. In the postgenomic era
of network cancer biology,4 and with the advent of
the new high-throughput technologies language,
methodologies and research directions should be al-
tered for a faster clinical success.5–10
Currently, a comprehensive bench-to-bedside
genomic-based model for personalized treatment of
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gastric cancer has been developed and proposed by
Roukos.11 This protocol has been focused on how to
overcome current treatment challenges and biases
associated with high-throughput analyses. As re-
ported above, the vast majority of patients received
an inadequate adjuvant treatment either because they
do not need adjuvant systemic treatment, they have a
localized nature of disease, or they do not respond to
currently used cytotoxic chemotherapy. Focusing on
these clinical needs, cancer genome and functional
strategies are integrated to reveal the precise role of
key genes and interacting pathways.4–10 The pro-
posed model can lead to the development of class II
prognostic and class III predictive biomarkers.38
Proﬁling involved gastric cancer key genes, driver
mutations, and interacting pathways will improve our
understanding on signaling pathways network. In-
sights into the presence or absence of small cells
subpopulations like cells with high mutation rates or
cancer stem-like cells in individual tumors will clarify
resistance and sensitivity to cytotoxic and targeted
agents. Taken together, the development of both
novel biomarkers and targeted agents can be
achieved. Prognostic gene signatures might classify
patients into low and high metastatic risk. Low-risk
patients can successfully be treated by R0 surgery
alone, sparing unnecessary chemotherapy toxicity.
Among patients at high risk of metastatic relapse,
predictive gene signatures can be developed com-
paring tissue-bank samples from responding and
nonresponding patients. The fact that the protocol
has considered, from the very initiating stage of de-
sign, the current robust clinicopathological factors
including the Lauren classiﬁcation into intestinal-
type and diffuse-type gastric cancer, enables the
clinical prospective validation of new biomarkers.11
CURRENT CLINICAL PRACTICE
Although cancer genome and functional studies
provide great promise for the future, patients and
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FIG. 1. Flow chart for decision-making regarding adjuvant treatment for resectable gastric cancer. aD2 surgery if surgeons experience
ensures a safe and effective procedure. If a standardized D2 surgery is not feasible, D1 surgery with chemoradiotherapy3 or preoperative
chemotherapy2 can be considered. bAdjuvant treatment: Cisplatin-based chemotherapy for Western patients, S-1 chemotherapy for East
Asian patients. Addition of targeted agents to empirical chemotherapy only in randomized trials. RCTs: randomized controlled trials.
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clinicians are currently face hard decisions: preoper-
ative or postoperative chemotherapy combined with
D2 surgery or D1 plus radiotherapy? Considering the
preclinical and clinical evidence, a step-by-step
treatment-guided algorithm for Western clinical
practice is provided (Fig. 1). Laparoscopy is clinically
useful to conﬁrm by biopsy or exclude distant
metastasis (peritoneum, liver, distant abdominal en-
larged lymph nodes) and serosa status (serosa nega-
tive or positive) for more accurate staging than
clinical staging with endoscopic ultrasonography,
computer tomography or positron emission tomog-
raphy (PET). Analysis of data from randomized
clinical trials (RCTs)1–3,39 and descriptive studies
show that, ﬁrst, survival rates for stage II patients are
relatively good not only in Japan1,13 but also in the
West18,19,40 with appropriate surgery followed by
adjuvant treatment. Because preoperative chemo-
therapy harms some of these patients,22 primary D2
surgery without delay, converting laparoscopy into
an open D2 gastrectomy, now appears to be the
preferred approach. Laparoscopic-assisted D2 gas-
trectomy provides encouraging data but feasibility,
safety, and efﬁcacy can be ensured at the present time
only in a few highly specialized institutions.41 Second,
because postoperative S-1 chemotherapy for stages
IIIA and IIIB did not signiﬁcantly improve survival
in the subgroup analysis of the ACTS-GC study,1
preoperative cisplatin-based chemotherapy for
downstaging and potential early elimination of cir-
culated cancer cells2 could be considered, although no
subgroup analysis from the MAGIC trial is available.
CONCLUSIONS
Gastric cancer still remains a major health prob-
lem. Despite improvements in local control and
empirical chemotherapy, prognosis particularly for
stage III patients remains poor worldwide. New
therapeutic strategies are needed.
In the postgenomic era of network cancer biology,
clinical practice could be altered when the catalogue
of gastric cancer genes has been completed and new
high-throughput analyses reveal the whole genome
function, including the understanding of noncoding
DNA regions. In the meantime, microarray-based
and proteomics data proﬁling genes, mutations, and
interacting oncogenic signaling pathways may lead to
the development and validation of both biologically
targeted agents and prognostic class II and predictive
class III biomarkers. Tailoring the best preoperative
or postoperative combination of empirical cytotoxic
and targeted agents distinctly diﬀerent in various
subsets of individual tumors on the basis of which
genes are involved and which pathways are deregu-
lated in a give patient, then indeed personal cancer
genome and personalized oncology will revolutionize
clinical outcomes not only of gastric cancer but also
most solid cancers.11
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